Clinical significance of extended-spectrum β-lactamases

References

• Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis.31(Suppl. 4), S131–S138 (2006).
   Google Scholar
• Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am. J. Med.119(6 Suppl. 1), S20–S22 (2006).
   PubMed Web of Science ®Google Scholar
• Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Soceity of Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis.44(2), 159–177 (2007).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev.18(4), 657–686 (2005).
   PubMed Web of Science ®Google Scholar
• Cantón R, Coque TM. The CTX-M β-lactamase pandemic. Curr. Opin. Microbiol.9(5), 466–475 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis JS II, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob. Agents Chemother.51(11), 4015–4021 (2007).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Cantón R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother.59(2), 165–175 (2007).
   PubMed Web of Science ®Google Scholar
• Naas T, Poirel L, Nordmann P. Minor extended-spectrum β-lactamases. Clin. Microbiol. Infect.14(Suppl. 1), 42–52 (2008).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Paterson DL. A change in the epidemiology of infections due to extended-spectrum β-lactamase-producing organisms. Clin. Infect. Dis.42(7), 935–937 (2006).
   PubMed Web of Science ®Google Scholar
• Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann. Intern. Med.136(11), 834–844 (2002).
   PubMed Web of Science ®Google Scholar
• Rogues AM, Boulard G, Allery A et al. Thermometers as a vehicle for transmission of extended-spectrum β-lactamase-producing Klebsiella pneumoniae.J. Hosp. Infect.45(1), 76–77 (2000).
   PubMed Web of Science ®Google Scholar
• Macrea MB, Shannon KP, Rayner DM, Kaiser AM, Hoffman PN, French GL. A simultaneous outbreak on a neonatal unit of two strains of multiply antibiotic resistant Klebsiella pneumoniae controllable only by ward closure. J. Hosp. Infect.49(3), 183–192 (2001).
   PubMed Web of Science ®Google Scholar
• Harris AD, Perencevich EN, Johnson JK et al. Patient-to-patient transmission is important in extended-spectrum β-lactamase-producing Klebsiella pneumoniae acquisition. Clin. Infect. Dis.45(10), 1347–1350 (2007).
   PubMed Web of Science ®Google Scholar
• Valverde A, Coque MT, Sánchez-Moreno MP et al. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situation in Spain. J. Clin. Microbiol.42(10), 4769–4775 (2004).
   PubMed Web of Science ®Google Scholar
• Miró E, Mirelis B, Navarro F et al. Surveillance of extended-spectrum β-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J. Antimicrob. Chemother.56(6), 1152–1155 (2005).
   PubMed Web of Science ®Google Scholar
• Castillo García FJ, Seral García C, Pardos de la Gándara M et al. Prevalence of fecal carriage of ESBL-producing Enterobacteriaceae in hospitalized and ambulatory patients during two non-outbreak periods. Eur. J. Clin. Microbiol. Infect. Dis.26(1), 77–78 (2007).
   PubMed Web of Science ®Google Scholar
• Kader AA, Kumar A, Kamath KA. Fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in patients and asymptomatic healthy individuals. Infect. Control Hosp. Epidemiol.28(9), 1114–1116 (2007).
   PubMed Web of Science ®Google Scholar
• Pallecchi L, Bartoloni A, Fiorelli C et al. Rapid dissemination and diversity of CTX-M extended-spectrum β-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America. Antimicrob. Agents Chemother.51(8), 2720–2725 (2007).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, López-Cerero L, Navarro MD, Díaz de Alba P, Pascual A. Faecal carriage of extended-spectrum β-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J. Antimicrob. Chemother. PMID: 18641033 (2008) (Epub ahead of print).
   Google Scholar
• Mesa RJ, Blanc V, Blanch AR et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage). J. Antimicrob. Chemother.58(1), 211–215 (2006).
   PubMed Web of Science ®Google Scholar
• Doi Y, Paterson DL, O´Keefe A et al. Cephalosporin-resistant Escherichia coli from retail meat in Spain and the United States. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA 17–20 (2007).
   Google Scholar
• Warren RE, Ensor VM, O´Neill P et al. Imported chicken as a potential source of quinolone-resistant Escherichia coli producing extended-spectrum β-lactamases in the UK. J. Antimicrob. Chemother.61(3), 504–508 (2008).
   PubMed Web of Science ®Google Scholar
• Romero L, López L, Rodríguez-Baño J et al. Long term study of the frequency of extended-spectrum β-lactamases-producing Escherichia coli and Klebsiella pneumoniae isolates. Clin. Microbiol. Infect.11(8), 625–631 (2005).
   PubMed Web of Science ®Google Scholar
• Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J. Antimicrob. Chemother.56(1), 52–59 (2005).
   PubMed Web of Science ®Google Scholar
• Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J. Antimicrob. Agents61(2), 273–281 (2008).
   Google Scholar
• Hernández JR, Martínez-Martínez L, Cantón R, Coque TM, Pascual A; the Spanish Group for Nosocomial Infections (GEIH). Nationwide study of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases in Spain. Antimicrob. Agents Chemother.49(5), 2122–2125 (2005).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Navarro MD, Romero L et al. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin. Infect. Dis.42(1), 37–45 (2006).
   PubMed Web of Science ®Google Scholar
• Peña C, Gudiol C, Tubau F et al. Risk-factors for acquisition of extended-spectrum β-lactamase-producing Escherichia coli among hospitalized patients. Clin. Microbiol. Infect.12(3), 279–284 (2006).
   PubMed Web of Science ®Google Scholar
• Cantón R, Oliver A, Coque TM, Varela MC, Pérez-Díaz JC, Baquero F. Epidemiology of extended-spectrum β-lactamase-producing isolates in a Spanish hospital during a 12-year period. J. Clin. Microbiol.40(4), 1237–1243 (2002).
   PubMed Web of Science ®Google Scholar
• Valverde A, Coque MT, García San Miguel L, Baquero F, Cantón R. Complex molecular epidemiology of extended-spectrum β-lactamases in Klebsiella pneumoniae: a long-term perspective from a single institution in Madrid. J. Antimicrob. Chemother.61(1), 64–72 (2008).
   PubMed Web of Science ®Google Scholar
• Garcia D de O, Doi Y, Szabo D et al. Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum β-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. Antimicrob. Agents Chemother.52(5), 1790–1793 (2008).
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Schwaber MJ, Navon-Venezia S et al. Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin. Infect. Dis42(7), 925–934 (2006).
   PubMed Web of Science ®Google Scholar
• Harris AD, Kotetishvilli M, Shurland S et al. How important is patient-to-patient transmission in extended-spectrum β-lactamase Escherichia coli acquisition. Am. J. Infect. Control35(2), 97–191 (2007).
   PubMed Web of Science ®Google Scholar
• Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn. Microbiol. Infect. Dis.61(2), 203–213 (2008).
   PubMed Web of Science ®Google Scholar
• Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn. Microbiol. Infect. Dis.60(2), 185–192 (2008).
   PubMed Web of Science ®Google Scholar
• Hirakata Y, Matsuda J, Miyazaki Y et al. Regional variation in the prevalence of extended-spectrum β-lactamase-producing clinical isolates in the Asia–Pacific region (SENTRY 1998–2002). Diagn. Microbiol. Infect. Dis.52(4), 323–329 (2005).
   PubMed Web of Science ®Google Scholar
• Rossi F, Baquero F, Hsueh PR et al.In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J. Antimicrob. Chemother.58(1), 205–120 (2006).
   PubMed Web of Science ®Google Scholar
• Behar PRP, Texeira PJZ, Fachel JMG, Falid AC. The effect of control group selection in the analysis of risk factors for extended-spectrum β-lactamase-producing Klebsiella pneumoniae infections. A prospective controlled study. J. Hosp. Infect.68(2), 123–129 (2008).
   PubMed Web of Science ®Google Scholar
• Harris AD, Karchmer TB, Carmeli Y, Samore SH. Methodological principles of case–control studies that analysed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis.32(7), 1055–1061 (2001).
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Clinical and molecular epidemiology of community-onset, extended-spectrum β-lactamase-producing Escherichia coli infections in Thailand: a case–case–control study. Am. J. Infect. Control35(9), 606–612 (2007).
   PubMed Web of Science ®Google Scholar
• Rodríguez Baño J, Navarro MD, Romero L et al. Risk factors for emerging bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli.Clin. Microbiol. Infect.14(2), 180–183 (2008).
   PubMed Web of Science ®Google Scholar
• Ling MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum β-lactamase Klebsiella pneumoniae: a case–control study in a district teaching hospital in Taiwan. J. Hosp. Infect.53(1), 39–45 (2003).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Ko WC, Von Gottberg A et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann. Intern. Med.140(1), 26–32 (2004).
   PubMed Web of Science ®Google Scholar
• Lee SO, Lee ES, Park SY, Kim SY, Seo Y, Cho YK. Reduced use of third generation cephalosporins decreased the acquisition of extended-spectrum β-lactamase producing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol.25(10), 832–837 (2004).
   PubMed Web of Science ®Google Scholar
• Kang CI, Ki SH, Kim DM et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol.25(10), 860–867 (2004).
   PubMed Web of Science ®Google Scholar
• Silva N, Oliveira M, Bandeira AC, Brites C. Risk factors for infection by extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a tertiary hospital in Salvador, Brazil. Braz. J. Infect. Dis.10(3), 191–193 (2006).
   PubMedGoogle Scholar
• Peña C, Pujol M, Ricart A et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended-spectrum β-lactamase (ESBL-KP) in the intensive care unit. J. Hosp. Infect.35(1), 9–16 (1997).
   PubMed Web of Science ®Google Scholar
• Rebuck JA, Olsen KM, Fey PD, Langas AN, Rupp ME. Characterization of an outbreak due to extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin. Infect. Dis.31(6), 1368–1372 (2000).
   PubMed Web of Science ®Google Scholar
• Asensio A, Oliver A, González-Diego P et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. Clin. Infect. Dis.30(1), 55–60 (2000).
   PubMed Web of Science ®Google Scholar
• Gupta A, Della-Latta P, Todd B et al. Outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit linked to artificial nails. Infect. Control Hosp. Epidemiol.25(3), 210–215 (2004).
   PubMed Web of Science ®Google Scholar
• Boo NY, Ng SG, Lim VK. A case–control study of risk factors associated with rectal colonization of extended-spectrum β-lactamase-producing Klebsiella spp. in newborn infants. J. Hosp. Infect.61(1), 68–74 (2005).
   PubMed Web of Science ®Google Scholar
• Kuo KC, Shen YH, Hwang KP. Clinical implications and risk factors of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection in children; a case–control retrospective study in a medical center in southern Taiwan. J. Clin. Immunol. Infect.40(3), 248–254 (2007).
   Google Scholar
• Kristóf K, Szabó D, Marsh JW et al. Extended-spectrum β-lactamase-producing Klebsiella spp. in a neonatal intensive care unit: risk factors for the infection and the dynamics of the molecular epidemiology. Eur. J. Clin. Microbiol. Infect. Dis.26(8), 563–570 (2007).
   PubMed Web of Science ®Google Scholar
• Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli producing extended-spectrum β-lactamases: importance of community isolates with blaCTX-M genes. Clin. Infect. Dis.38(12), 1736–1741 (2004).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in non-hospitalized patients. J. Clin. Microbiol.42(3), 1089–1094 (2004).
   PubMed Web of Science ®Google Scholar
• Calbo E, Romaní V, Xercavins M et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases. J. Antimicrob. Chemother.57(4), 780–183 (2006).
   PubMed Web of Science ®Google Scholar
• Colodner R, Rock W, Chazan B, Keller N, Guy N, Raz R. Risk factors for the development of extended-spectrum β-lactamase-producing bacteria in non-hospitalized patients. Eur. J. Clin. Microbiol. Infect. Dis.23(3), 163–167 (2004).
   PubMed Web of Science ®Google Scholar
• Ena J, Arjona F, Martínez-Peinado C, López-Perazagua Mdel M, Amador C. Epidemiology of urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Urology68(6), 11169–11174 (2006).
   Google Scholar
• Moor CT, Roberts SA, Simmons G et al. Extended-spectrum β-lactamase (ESBL)-producing enterobacteria; factors associated with infection in the community setting, Auckland, New Zealand. J. Hosp. Infect.68(4), 355–362 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Baño J, Alcalá JC, Cisneros JM et al. Community infections caused by extended-spectrum β-lactamase producing-Escherichia coli. Arch. Intern. Med. (2008) (In press).
   PubMedGoogle Scholar
• Ho PL, Chan WM, Tsang KW, Wong SS, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a case–control study of risk factors and outcomes. Scand. J. Infect. Dis.34(8), 567–573 (2002).
   PubMed Web of Science ®Google Scholar
• Peña C, Pujol M, Ardanuy C et al. An outbreak of hospital acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum β-lactamase. J. Hosp. Infect.47(1), 53–59 (2001).
   PubMed Web of Science ®Google Scholar
• Peña C, Pujol M, Ardanuy C et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob. Agents Chemother.42(1), 53–58 (1998).
   PubMed Web of Science ®Google Scholar
• Hyle EP, Lipwoth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Arch. Intern. Med.165(12), 1375–1380 (2005).
   PubMedGoogle Scholar
• Garcia San Miguel L, Cobo J, Valverde A et al. Clinical variables associated with the isolation of Klebsiella pneumoniae expressing different extended-spectrum β-lactamases. Clin. Microbiol. Infect.13(5), 532–538 (2007).
   PubMed Web of Science ®Google Scholar
• Richards C, Alonso-Echanove J, Caicedo Y, Jarvis WR. Klebsiella pneumoniae bloodstream infections among neonates in a high-risk nursery in Cali, Colombia. Infect. Control Hosp. Epidemiol.25(3), 221–225 (2004).
   PubMed Web of Science ®Google Scholar
• Reddy P, Malcynski M, Obias A et al. Screening for extended-spectrum β-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin. Infect. Dis.45(7), 846–852 (2007).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, García L, Durán L et al. Control of an extensive and prolonged outbreak caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a neonatal unit. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 27–30 September (2006).
   Google Scholar
• Kim JBN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteraemia. J. Hosp. Infect.52(2), 99–106 (2002).
   PubMed Web of Science ®Google Scholar
• Marra AR, Wey SB, Castelo A et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect. Dis.6, 24 (2006).
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Spanu T, Sanguinetti M et al. Bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob. Agents Chemother.50(2), 498–504 (2006).
   PubMed Web of Science ®Google Scholar
• McMullan R, Loughrey AC, McCalmont M, Rooney PJ. Clinico-epidemiological features of infections caused by CTX-M type extended-spectrum β-lactamase-producing Escherichia coli in hospitalised patients. J. Infect.54(1), 46–52 (2007).
   PubMed Web of Science ®Google Scholar
• Hernández JR, Pascual A, Cantón R, Martínez-Martínez L; Grupo de Estudio de Infección Hospitalaria (GEIH). Escherichia coli y Klebsiella pneumoniae productores de β-lactamasas de espectro extendido en hospitales españoles (proyecto GEIH-BLEE 2000). Enferm. Infecc. Microbiol. Clin.21(2), 77–82 (2003).
   PubMed Web of Science ®Google Scholar
• Metan G, Zarakolu P, Cakir B, Hascelik G, Uzun O. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Int. J. Antimicrob. Agents26(3), 254–257 (2005).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis.43(11), 1407–1414 (2006).
   PubMed Web of Science ®Google Scholar
• Bin C, Hui W, Renyuan Z et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M type extended-spectrum β-lactamase-producing Escherichia coli. Diag. Microbiol. Infect. Dis.56(4), 351–357 (2006).
   PubMed Web of Science ®Google Scholar
• Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Eur. J. Clin. Microbiol. Infect. Dis.27(1), 85–88 (2008).
   PubMed Web of Science ®Google Scholar
• Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended-spectrum β-lactamase (ESBL) producing E. coli compared with non-ESBL producing E. coli. J. Infect.55(3), 254–259 (2007).
   PubMed Web of Science ®Google Scholar
• Hammami A, Arlet G, Ben Redjeb S et al. Nosocomial outbreak of acute gastroenteritis in a neonatal intensive care unit in Tunisia caused by multiply drug resistant Salmonella wien producing SHV-2 β-lactamase. Eur. J. Clin. Microbiol. Infect. Dis.10(8), 641–646 (1991).
   PubMed Web of Science ®Google Scholar
• Morisini MI, Blázquez J, Negri MC, Cantón R, Loza E, Baquero F. Characterization of a nosocomial outbreak involving an epidemic strain encoding for TEM-27 in Salmonella enterica serotype Othmarchen. J. Infect. Dis.174(5), 1015–1020 (1996).
   PubMed Web of Science ®Google Scholar
• Bouallegue-Godet O, Ben Salem Y, Fabre L et al. Nosocomial outbreak caused by Salmonella enterica serotype Livingstone producing CTX-M-27 extended-spectrum β-lactamase in a neonatal unit in Sousse, Tunisia. J. Clin. Microbiol.43(3), 1037–1044 (2005).
   PubMed Web of Science ®Google Scholar
• Yong D, Lim YS, Yum JH et al. Nosocomial outbreal of pediatric gastroenteritis caused by CTX-M-14-type extended-spectrum β-lactamase-producing Salmonella enterica serovar London. J. Clin. Microbiol.43(7), 3519–3521 (2005).
   PubMed Web of Science ®Google Scholar
• Wadula J, Von Gotteberg A, Kilner D et al. Nosocomial outbreak of extended-spectrum β-lactamase-producing Salmonella isangi in pediatric wards. Pediatr. Infect. Dis. J.25(9), 843–844 (2006).
   PubMed Web of Science ®Google Scholar
• Endimiani A, Luzzaro F, Brigante G et al.Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases. Antimicrob. Agents Chemother.49(7), 2598–2605 (2005).
   PubMed Web of Science ®Google Scholar
• Manzur A, Tubau F, Pujol M et al. Nosocomial outbreak due to extended-spectrum β-lactamase-producing Enterobacter cloacae in a cardiothoracic intensive care unit. J. Clin. Microbiol.45(8), 2364–2369 (2007).
   Google Scholar
• Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother.60(5), 913–920 (2007).
   PubMed Web of Science ®Google Scholar
• Marcos M, Soriano A, Martínez JA, Mensa J. Septic shock should be included in multivariable analysis models analysing the effect of empirical antibiotic therapy of mortality. Clin. Infect. Dis.45(10), 1410 (2007).
   Google Scholar
• Lavigne JP, Blanc-Potard AB, Bourg G et al. Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M β-lactamases. Clin. Microbiol. Infect.12(12), 1199–1206 (2006).
   PubMed Web of Science ®Google Scholar
• Karisik E, Ellington MJ, Livermore DM, Woodford N. Virulence factors in Escherichia coli with CTX-M-15 and other extended-spectrum β-lactamases in UK. J. Antimicrob. Chemother.61, 54–50 (2008).
   PubMed Web of Science ®Google Scholar
• Clermont O, Lavollay M, Vimont S et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J. Antimicrob. Agents61, 1024–1028 (2008).
   Google Scholar
• Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz C, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother.50(4), 1257–1262 (2006).
   PubMed Web of Science ®Google Scholar
• Peña C, Gudiol C, Calatayud L et al. Infections due to Escherichia coli producing extended-spectrum β-lactamase among hospitalised patients: factors influencing mortality. J. Hosp. Infect.68(2), 116–122 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson DJ, Engemann JJ, Harrel LJ, Carmeli Y, Barth Reller L, Kaye KS. Predictors of mortality in patients with bloodstream infections due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob. Agents Chemother.50(5), 1715–1720 (2006).
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sanguinetti M, Montuori E et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother.51(6), 1987–1994 (2007).
   PubMed Web of Science ®Google Scholar
• Peralta G, Sánchez MB, Garrido JC et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteremia. J. Antimicrob. Chemother.60(4), 855–863 (2007).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Ko WC, Von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol.39(6), 2206–2212 (2001).
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Hindler J, Loeloff M et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin. Infect. Dis.34(2), 135–146 (2002).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Ko WC, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin. Infect. Dis.39(1), 31–37 (2004).
   PubMed Web of Science ®Google Scholar
• Endimiani A, Luzzaro F, Perilli M et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin. Infect. Dis.38(2), 243–251 (2004).
   PubMed Web of Science ®Google Scholar
• Frei CR, Wiederhold N, Burgess DS. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic–pharmacodymanic models with Monte Carlo simulations. J. Antimicrob. Chemother.61(3), 621–628 (2008).
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Methods For Dilution Antimicrobial Susceptibility Test For Bacteria That Grow Aerobically (7th Edition). Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2006).
   Google Scholar
• Hernández JR, Velasco C, Romero L, Martínez-Martínez L, Pascual A. Comparative in vitro activity of ertapenem against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain. Int. J. Antimicrob. Agents28(5), 457–459 (2006).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Fasce R et al. Efficacy of ertapenem in the treatment if early ventilator-associated pneumonia caused by extended-spectrum β-lactamase-producing organisms in an intensive care unit. J. Antimicrob. Chemother.60(2), 433–435 (2007).
   PubMed Web of Science ®Google Scholar
• Teng CP, Chen HH, Chan J, Lye DC. Ertapenem for the treament of extended-spectrum β-lactamase-producing Gram-negative bacterial infections. Int. J. Antimicrob. Agents30(4), 356–359 (2007).
   PubMed Web of Science ®Google Scholar
• Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum β-lactamase-producing Gram-negative infections: a case series report. Ann. Pharmacother.42(2), 207–212 (2008).
   PubMed Web of Science ®Google Scholar
• Szabo D, Silveira F, Hujer AM et al. Outer membrane protein changes and efflux pump expression together may confer resistence to ertapenem in Enterobacter cloacae. Antimicrob. Agents Chemother.50(8), 2833–2835 (2006).
   PubMed Web of Science ®Google Scholar
• Elliot E, Brink AJ, Van Greune J et al.In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum β-lactamase. Clin. Infect. Dis.42(11), E95–E98 (2006).
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin. Microbiol. Infect.11(Suppl. 6), 10–17 (2005).
   PubMed Web of Science ®Google Scholar
• MacGowan A. Breakpoints for extended-spectrum β-lactamase-producing Enterobacteriaceae: pharmaco­kinetic/pharmaco­dynamic considerations. Clin. Microbiol. Infect.14(Suppl. 1), 166–168 (2008).
   PubMed Web of Science ®Google Scholar
• Karisik E, Ellington MJ, Pike R, Warren RE, Livermore DM, Woodford N. Molecular characterization of plasmids encoding CTX-M-15 β-lactamases from Escherichia coli strains in the United Kingdom. J. Antimicrob. Chemother.58(3), 665–668 (2006).
   PubMed Web of Science ®Google Scholar
• Doménech-Sánchez A, Pascual A, Suárez AI, Alvarez D, Benedí VJ, Martínez?Martínez L. Activity of nine antimicrobial agents against clinical isolates of Klebsiella pneumoniae producing extended-spectrum β-lactamases and deficient or not in porins. J. Antimicrob. Chemother.46(5), 858–859 (2000).
   PubMed Web of Science ®Google Scholar
• Sader HS, Hsiung A, Fritsche TR, Jones RN. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diag. Microbiol. Infect. Dis.57(3), 341–344 (2007).
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics–pharmacodynamics of cefepime and piperacillin–taxobactam against Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob. Agents Chemother.47(5), 1643–1646 (2003).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J. Antimicrob. Chemother.56(3), 451–454 (2005).
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis.6(9), 589–601 (2006).
   PubMed Web of Science ®Google Scholar
• Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert Rev. Anti Infect. Ther.4(4), 601–618 (2008).
   Google Scholar
• Morosini MI, Garcia-Castillo M, Coque TM et al. Antibiotic coresistance in extended-spectrum β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob. Agents Chemother.50(8), 2695–2699 (2006).
   PubMed Web of Science ®Google Scholar
• Livermore DM. Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother.56(4), 611–614 (2005).
   PubMed Web of Science ®Google Scholar
• Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J. Clin. Microbiol.46(5), 1892–1893 (2008).
   PubMed Web of Science ®Google Scholar
• Krueger WA, Kempf VA, Peiffer M, Nagele U, Unertl KE, Schroeder TH. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-β-lactamase-producing Escherichia coli. J. Clin. Microbiol.46(2), 817–820 (2008).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R et al.Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother.59(1), 128–131 (2007).
   PubMed Web of Science ®Google Scholar
• Cobo J, Morosini MI, Pintado V et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 β-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn. Microbiol. Infect. Dis.60(3), 319–322 (2008).
   PubMed Web of Science ®Google Scholar
• de Cueto M, Hernández JR, López-Cerero L, Morllo C, Pascual A. Actividad de fosfomicina sobre cepas de Escherichia coli y Klebsiella pneumoniae productoras de β-lactamasas de espectro extendido. Enferm. Infecc. Microbiol. Clin.24(10), 613–616 (2006).
   PubMed Web of Science ®Google Scholar
• Pullucku H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related urinary tract infections. Int. J. Antimicrob. Agents29(1), 62–65 (2007).
   PubMed Web of Science ®Google Scholar
• Garau J. Other antimicrobials of interest in the era of extended-spectrum β-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin. Microb. Infect.14(Suppl. 1), 198–202 (2008).
   Google Scholar